Encephalitis, Tick-borne Clinical Trial
Official title:
Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 6 to 16 Years
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all volunteers who completed two vaccinations in one of the three treatment groups of Baxter study 205 (safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy volunteers aged 6 to 16 years).
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01031537 -
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
|
Phase 2 | |
Completed |
NCT00460486 -
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
|
Phase 3 | |
Completed |
NCT00161824 -
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
|
Phase 3 | |
Completed |
NCT00161967 -
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
|
Phase 4 | |
Completed |
NCT00163540 -
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
|
Phase 4 | |
Completed |
NCT00161876 -
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
|
Phase 3 | |
Recruiting |
NCT03932448 -
Fever After Tick Bite Study
|
||
Completed |
NCT00311441 -
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
|
Phase 4 | |
Completed |
NCT00161954 -
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
|
Phase 4 | |
Completed |
NCT00163618 -
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
|
Phase 4 | |
Completed |
NCT00503529 -
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
|
Phase 4 | |
Completed |
NCT00840801 -
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
|
Phase 3 | |
Completed |
NCT00452621 -
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
|
Phase 4 | |
Completed |
NCT00311493 -
Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults
|
Phase 4 | |
Completed |
NCT00161850 -
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
|
Phase 2 | |
Completed |
NCT00894686 -
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
|
Phase 4 | |
Completed |
NCT00161746 -
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
|
Phase 2/Phase 3 |